ethyl (+/-)-(3R,4R)-1-benzyl-4-(trifluoromethyl)pyrrolidine-3-carboxylate | 152188-51-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: ethyl (+/-)-(3R,4R)-1-benzyl-4-(trifluoromethyl)pyrrolidine-3-carboxylate
• 英文别名: (3,4-trans)-ethyl-1-benzyl-4-(trifluoromethyl)pyrrolidine-3-carboxylate；1-benzyl-4-trifluoromethyl-pyrrolidine-3-carboxylic acid ethyl ester；(3S,4S)-Ethyl 1-benzyl-4-(trifluoromethyl)pyrrolidine-3-carboxylate；ethyl (3S,4S)-1-benzyl-4-(trifluoromethyl)pyrrolidine-3-carboxylate
• CAS: 152188-51-7
• 化学式: C₁₅H₁₈F₃NO₂
• 分子量: 301.309
• InChiKey: SJIVVBIUXVKZDK-CHWSQXEVSA-N

物化性质

• 沸点：
  314.1±42.0 °C(Predicted)
• 密度：
  1.228±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl (+/-)-(3R,4R)-1-benzyl-4-(trifluoromethyl)pyrrolidine-3-carboxylate 在 palladium on activated charcoal sodium hydroxide 、 lithium aluminium tetrahydride 、 氯化亚砜 、 氨 、 氢气 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 二甲基亚砜 为溶剂， 生成 7-[(3S,4R)-3-(tert-Butoxycarbonylamino-methyl)-4-trifluoromethyl-pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
  参考文献：
  名称：

  Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones

  摘要：

  The titled compounds were synthesized and evaluated for in vitro antibacterial activity. The (3R,4S)-3-aminomethyl-4-trifluoromethyl derivative (S-34109) was confirmed to be optimal because of its superior activity against quinolone and methicillin-resistant Staphyrococcus aureus and low side effect potential. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00514-9
• 作为产物：
  描述：

  4,4,4-三氟巴豆酸乙酯 、 N-(甲氧甲基)-N-(三甲基硅甲基)苄胺 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以99%的产率得到ethyl (+/-)-(3R,4R)-1-benzyl-4-(trifluoromethyl)pyrrolidine-3-carboxylate
  参考文献：
  名称：

  Bicyclic-Fused Heteroaryl or Aryl Compounds

  摘要：

  所述化合物的异构体和药学上可接受的盐已被披露，其中所述化合物具有如规范中定义的Ia式结构。相应的药物组合物、治疗方法、合成方法和中间体也已被披露。

  公开号：

  US20150284405A1

文献信息

• Bicyclic-Fused Heteroaryl or Aryl Compounds
  申请人：Pfizer Inc.

  公开号：US20150284405A1

  公开（公告）日：2015-10-08

  Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  所述化合物的异构体和药学上可接受的盐已被披露，其中所述化合物具有如规范中定义的Ia式结构。相应的药物组合物、治疗方法、合成方法和中间体也已被披露。
• Cyclic amines
  申请人：Zbinden Groebke Katrin

  公开号：US20060247238A1

  公开（公告）日：2006-11-02

  The invention is concerned with cyclic amines of formula (I) wherein X 1 to X 3 , Y 1 to Y 3 , R 1′ , R 1″ and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit coagulation factor Xa and can be used as medicaments and for treating diseases associated with coagulation factor Xa.

  这项发明涉及公式(I)中的环氨基化合物，其中X1至X3，Y1至Y3，R1'，R1"和n如描述和索赔中定义的那样，以及其生理上可接受的盐。这些化合物抑制凝血因子Xa，并可用作药物治疗与凝血因子Xa相关的疾病。
• AMINO-HETEROCYCLIC COMPOUNDS
  申请人：Verhoest Patrick R.

  公开号：US20090030003A1

  公开（公告）日：2009-01-29

  The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R, R 1 , R 2 and R 3 are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.

  该发明提供了式（I）的PDE9抑制化合物及其药用盐，其中R、R1、R2和R3如本文所定义。还提供了含有式I化合物的药物组合物，并将其用于治疗神经退行性和认知障碍，如阿尔茨海默病和精神分裂症。
• Quinolinecarboxylic acid derivatives and salts thereof
  申请人：Kaken Pharmaceutical Co., Ltd.

  公开号：US05668147A1

  公开（公告）日：1997-09-16

  Quinolinecarboxylic acid derivatives which are represented by the general formula (I) ##STR1## wherein R.sub.1 is a C.sub.1 to C.sub.6 alkyl group which may be substituted, a C.sub.2 to C.sub.6 alkenyl group which may be substituted, a C.sub.3 to C.sub.7 cycloalkyl group which my be substituted or an aryl group which may be substituted, R.sub.2 is hydrogen atom; a halogen atom; hydroxyl group which may be protected, amino group or a C.sub.1 to C.sub.6 alkylamino group each of which may be protected; a C.sub.1 to C.sub.6 dialkylamino group or a C.sub.1 to C.sub.6 alkyl group, R.sub.3 is hydrogen atom or a C.sub.1 to C.sub.6 alkyl group, A is nitrogen atom or ##STR2## wherein A' is hydrogen atom. a halogen atom, a C.sub.1 to C.sub.6 alkyl group, a C.sub.1 to C.sub.6 alkoxyl group which may be substituted, cyano group, or nitro group, and A' may form a ring with R.sub.1 ; the ring may include oxygen atom, nitrogen atom, or sulfur atom as a constituent atom; the ring may be substituted with a C.sub.1 to C.sub.6 alkyl group, X is hydroxymethyl group; aminomethyl group or amino group each of which may be protected, and salts thereof, and antibacterial agents which comprise the quinolinecarboxylic acid derivatives and salts thereof as active ingredients, and therapeutical methods thereby.

  通式（I）所代表的喹啉羧酸衍生物，其中R.sub.1是C.sub.1至C.sub.6烷基基团，可以是取代基；C.sub.2至C.sub.6烯基基团，可以是取代基；C.sub.3至C.sub.7环烷基团，可以是取代基；或芳基基团，可以是取代基。R.sub.2是氢原子；卤素原子；羟基，可以是保护基；氨基或C.sub.1至C.sub.6烷基氨基，每个可以是保护基；C.sub.1至C.sub.6二烷基氨基基团或C.sub.1至C.sub.6烷基基团，R.sub.3是氢原子或C.sub.1至C.sub.6烷基基团，A是氮原子或##STR2##其中A'是氢原子；卤素原子；C.sub.1至C.sub.6烷基基团；可以被取代的C.sub.1至C.sub.6烷氧基基团；氰基或硝基，A'可以与R.sub.1形成环；环可以包括氧原子、氮原子或硫原子作为组成原子；环可以被C.sub.1至C.sub.6烷基基团取代，X是羟甲基基团；氨甲基基团或氨基，每个可以是保护基，以及作为活性成分的喹啉羧酸衍生物及其盐的抗菌剂，以及其治疗方法。
• PYRROLOPYRIMIDINE AND PURINE DERIVATIVES
  申请人：Cheng Hengmiao

  公开号：US20130079324A1

  公开（公告）日：2013-03-28

  The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, T, V, W, X, Y, Z, ring A, R 1 , R 2 , R 3 , R 4 , R 5 , R 5a , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 and m are defined herein. There novel pyrrolopyrimidine and purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

  本发明涉及式（I）的化合物或其药学上可接受的盐，其中Q、T、V、W、X、Y、Z、环A、R1、R2、R3、R4、R5、R5a、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17和m均在此定义。这些新型吡咯吡嗪和嘌呤衍生物在哺乳动物中治疗异常细胞生长（如癌症）方面有用。另外，一些实施例涉及含有这些化合物的药物组合物以及在哺乳动物中治疗异常细胞生长的方法。